MA53541A - Dérivés hétéroaryles bicycliques - Google Patents

Dérivés hétéroaryles bicycliques

Info

Publication number
MA53541A
MA53541A MA053541A MA53541A MA53541A MA 53541 A MA53541 A MA 53541A MA 053541 A MA053541 A MA 053541A MA 53541 A MA53541 A MA 53541A MA 53541 A MA53541 A MA 53541A
Authority
MA
Morocco
Prior art keywords
bicyclic derivatives
heteroaryl bicyclic
heteroaryl
derivatives
bicyclic
Prior art date
Application number
MA053541A
Other languages
English (en)
Other versions
MA53541B1 (fr
Inventor
Jennifer Louise Carter
Hasane Ratni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA53541A publication Critical patent/MA53541A/fr
Publication of MA53541B1 publication Critical patent/MA53541B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA53541A 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques MA53541B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18192219 2018-09-03
PCT/EP2019/073303 WO2020048904A1 (fr) 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques

Publications (2)

Publication Number Publication Date
MA53541A true MA53541A (fr) 2021-12-08
MA53541B1 MA53541B1 (fr) 2024-02-29

Family

ID=63490310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53541A MA53541B1 (fr) 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques

Country Status (33)

Country Link
US (1) US12084461B2 (fr)
EP (1) EP3846903B1 (fr)
JP (1) JP7398435B2 (fr)
KR (1) KR102829709B1 (fr)
CN (1) CN112566696B (fr)
AR (1) AR116051A1 (fr)
AU (1) AU2019336492B2 (fr)
BR (1) BR112021002170A2 (fr)
CA (1) CA3107593A1 (fr)
CL (1) CL2021000486A1 (fr)
CO (1) CO2021002415A2 (fr)
CR (1) CR20210104A (fr)
DK (1) DK3846903T3 (fr)
ES (1) ES2966947T3 (fr)
FI (1) FI3846903T3 (fr)
HR (1) HRP20231663T1 (fr)
HU (1) HUE064554T2 (fr)
IL (1) IL281175B2 (fr)
LT (1) LT3846903T (fr)
MA (1) MA53541B1 (fr)
MX (1) MX2021002087A (fr)
MY (1) MY208133A (fr)
PE (1) PE20210860A1 (fr)
PH (1) PH12021550320A1 (fr)
PL (1) PL3846903T3 (fr)
PT (1) PT3846903T (fr)
RS (1) RS64950B1 (fr)
SG (1) SG11202102137SA (fr)
SI (1) SI3846903T1 (fr)
TW (1) TWI841592B (fr)
UA (1) UA128482C2 (fr)
WO (1) WO2020048904A1 (fr)
ZA (1) ZA202007831B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12275709B2 (en) 2018-12-27 2025-04-15 Hoffmann-La Roche Inc. Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994349A (en) 1997-10-27 1999-11-30 Howard University 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives
EP1422217A3 (fr) 1998-04-01 2004-06-16 Cardiome Pharma Corp. Composés aminocyclohexyle ether et leur utilisation
AU2528900A (en) 1999-02-12 2000-08-29 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
EP1218003A4 (fr) 1999-09-13 2004-02-11 David M Swope Composition et procede pour la reduction de la symptomatologie neurologique
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US8703753B2 (en) 2005-09-15 2014-04-22 Biomas Ltd. Use of tellurium compounds for the treatment of actinic keratosis
AU2008250436B2 (en) 2007-05-11 2013-03-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
BRPI0817433A2 (pt) 2007-10-19 2015-06-16 Janssen Pharmaceutica Nv Moduladores de gama-secretase piperidinila e piperazinila
US8673900B2 (en) 2008-11-13 2014-03-18 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201035101A (en) * 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
WO2010138901A1 (fr) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés
US20120142672A1 (en) * 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
EP2443657A4 (fr) 2009-09-04 2013-07-31 Hewlett Packard Development Co Memristances basées sur des composés métalliques à valence mixte
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
US9637491B2 (en) 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
JP6831372B2 (ja) 2015-09-09 2021-02-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 架橋ピペリジン誘導体
WO2017097728A1 (fr) 2015-12-10 2017-06-15 F. Hoffmann-La Roche Ag Dérivés de pipéridine pontés
JP7012715B2 (ja) 2016-06-27 2022-01-28 エフ.ホフマン-ラ ロシュ アーゲー γ-セクレターゼモジュレーターとしてのトリアゾロピリジン
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3535266B1 (fr) 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Dérivés hétéroaryle bicycliques
CN109790149B (zh) 2016-11-08 2022-05-17 豪夫迈·罗氏有限公司 苯氧基三唑类化合物
CN110337291A (zh) 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
CN111417636B (zh) 2018-01-22 2023-09-26 豪夫迈·罗氏有限公司 三唑并-氮杂䓬衍生物

Also Published As

Publication number Publication date
IL281175B1 (en) 2023-09-01
ZA202007831B (en) 2026-03-25
LT3846903T (lt) 2024-01-10
SG11202102137SA (en) 2021-04-29
EP3846903B1 (fr) 2023-10-25
JP7398435B2 (ja) 2023-12-14
TWI841592B (zh) 2024-05-11
MY208133A (en) 2025-04-17
CA3107593A1 (fr) 2020-03-12
JP2021535178A (ja) 2021-12-16
EP3846903A1 (fr) 2021-07-14
DK3846903T3 (da) 2024-01-02
US12084461B2 (en) 2024-09-10
CR20210104A (es) 2021-04-19
PE20210860A1 (es) 2021-05-18
HRP20231663T1 (hr) 2024-03-15
HUE064554T2 (hu) 2024-03-28
RS64950B1 (sr) 2024-01-31
CL2021000486A1 (es) 2021-07-30
CO2021002415A2 (es) 2021-03-08
PL3846903T3 (pl) 2024-05-06
IL281175B2 (en) 2024-01-01
AU2019336492B2 (en) 2024-10-31
PH12021550320A1 (en) 2021-10-04
TW202023649A (zh) 2020-07-01
AU2019336492A1 (en) 2021-01-07
UA128482C2 (uk) 2024-07-24
FI3846903T3 (fi) 2023-12-19
CN112566696A (zh) 2021-03-26
CN112566696B (zh) 2024-01-16
MX2021002087A (es) 2021-04-28
SI3846903T1 (sl) 2024-02-29
WO2020048904A1 (fr) 2020-03-12
AR116051A1 (es) 2021-03-25
MA53541B1 (fr) 2024-02-29
PT3846903T (pt) 2023-12-14
US20210323980A1 (en) 2021-10-21
ES2966947T3 (es) 2024-04-25
IL281175A (en) 2021-04-29
KR102829709B1 (ko) 2025-07-04
BR112021002170A2 (pt) 2021-05-04
KR20210054515A (ko) 2021-05-13

Similar Documents

Publication Publication Date Title
PT3958977T (pt) Derivados de camptotecina
DK3956033T3 (da) Bicykliske forbindelser
PL3897842T3 (pl) Pochodne bicykliczne
DK3728252T3 (da) 4-azaindolforbindelser
PT3687999T (pt) Derivados de rapamicina
MA41898A (fr) Dérivés de quinazolinone bicyclique
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP3457851A4 (fr) Dérivés de sobétirome
PL4013751T3 (pl) Pochodne 2-hydroksycykloalkano-1-karbamoilu
EP3654987A4 (fr) Utilisation de dérivés aminoalkylbenzothiazépine
HUE062157T2 (hu) Tumorellenes vegyületek
DK3768669T3 (da) Piperazinazaspiroderivater
EP4077334C0 (fr) Dérivés furoindazole
EP4021904C0 (fr) Dérivés d'alpha-d-galactopyranoside
PL3898637T3 (pl) Pochodne rapamycyny
EP3884940A4 (fr) Nouveau dérivé d'imidazole
EP3617195A4 (fr) Nouveaux dérivés de tétrahydronaphtyle urée
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3885347A4 (fr) Dérivé de dihydropyrrolopyrazole
EP3554637A4 (fr) Dérivés de spiropipéridine
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
PT3796975T (pt) Derivados de sulfonilaminobenzamida
MA56504A (fr) Dérivés de pyridin-3-yle
DK3894410T3 (da) Substituerede xanthinderivater
EP3472151A4 (fr) Dérivés de prolinamide carbocycliques